TAG:
in vitro diagnostic
2.3% Medical Device Tax Hits Clinical Labs in 2013
By Robert Michel | From the Volume XVII No. 5 – March 29, 2010 Issue
CEO SUMMARY: One aspect of the massive new health bill is that medical device companies will pay a 2.3% tax, effective January 1, 2013. Students of economics know that it is customers who invariably end up paying such direct taxes. Thus, clinical laboratories in the United States should p…
Preparing for New Lab Role In Personalized Medicine
By Robert Michel | From the Volume XVII No. 4 – March 8, 2010 Issue
CEO SUMMARY: Laboratory medicine is about to find itself between the two jaws of a powerful vise. One jaw is pending major legislative overhaul of the entire healthcare system, along with dwindling reimbursement as Medicare and Medicaid runs out of money. The other jaw is personalized med…
January 25, 2010 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XVII No. 2 – January 25, 2010 Issue
Probably few pathologists know that a musical group in San Diego, California, is performing under the name “Pathology.†It is classified as an American death metal band. Alert readers will notice a theme in this band’s output. In 2006, it released its debut album, called “Surgically Hacked, 
New Clinical Lab Trends To Shape Events in 2010
By Robert Michel | From the Volume XVII No. 1 – January 4, 2010 Issue
CEO SUMMARY: In presenting this list of macro trends for clinical laboratories, several themes are in play. They range from a continued emphasis on improving lab operations to the need to acquire and deploy sophisticated information technology. During the next few years, the long…
IBM, Cal Tech, E-Patients, Qiagen, Digene, SABiosciences
By Robert Michel | From the Volume XVI No. 17 – December 14, 2009 Issue
DNA NANOCHIP IS GOAL OF IBM SCIENTISTS ADVANCES IN GENETIC AND MOLECULAR TECHNOLOGIES are giving pathologists new tools for diagnosing disease and guiding therapy. But what often receives less attention is how genetic and molecular technologies are finding applications in other scientific fi…
2009’s Top Ten Lab Stories Reflect Some Good, Bad
By Robert Michel | From the Volume XVI No. 17 – December 14, 2009 Issue
CEO SUMMARY: As the closing year of the first decade of the new century and the new millennium, 2009 brought neither disruption nor upheaval to the majority of laboratories in the United States. Rather, it was marked by at least two themes. One was how public disclosure of problems with l…
GSK and Abbott Team up For Companion Diagnostic
By Robert Michel | From the Volume XVI No. 14 – October 12, 2009 Issue
CEO SUMMARY: Although GlaxoSmithKline PLC is several years away from having a deliverable product from its Antigen Specific Cancer Immunoassay (ASCI) Program, it has a development deal with Abbott Laboratories to produce a companion diagnostic test for ASCI-based products. The in…
New Lab Player Launches In Breast Cancer Market
By Robert Michel | From the Volume XVI No. 11 – August 10, 2009 Issue
CEO SUMMARY: Having opened its CLIA-licensed laboratory in Huntington Beach, California, Agendia, Inc., becomes the newest competitor to enter the market for breast cancer testing. Its proprietary assay looks at 70 genes to assess the risk of recurrence. The company expects to co…
Mickey Mouse to Educate Kids About Allergy Lab Test Options
By Robert Michel | From the Volume XVI No. 8 – June 8, 2009 Issue
THIS MAY BE A FIRST IN LABORATORY TEST SALES AND MARKETING! Mickey Mouse will star in a new children’s book designed to educate children and parents about diagnosis and management of allergies. This unique marketing campaign is the brainchild of Siemens Healthcare and Walt…
New Report: POC Market Will Grow 30% by 2013
By Robert Michel | From the Volume XVI No. 7 – May 18, 2009 Issue
CEO SUMMARY: It will be no surprise to lab directors and pathologists that Kalorama Information, in its latest report on point-of-care (POC) testing, estimates that glucose testing comprises 67% of this market segment. What is notable is Kalorama’s prediction that worldwide POC…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized